ArticleFrontiers in oncology2025
Proton therapy achieves high-dose tumor control with organ preservation in complex metastatic adenoid cystic carcinoma: a case report of a refractory patient with 16 pulmonary metastases.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid Cystic Carcinoma (ACC) is characterized by its aggressive nature, high propensity for perineural invasion, and significant risk of distant metastasis, particularly to the lungs. Therapeutic options for locally advanced or metastatic ACC are limited, and conventional radiotherapy is often constrained by dose limitations for multifocal disease, leading to inadequate treatment. A 54-year-old male ACC patient, who had recurred after three prior surgeries, presented with PET/CT-confirmed bilateral cervical lymph node and multiple bilateral pulmonary metastases. Given the multifocal metastases and the critical need for sparing organs at risk (lungs, heart, esophagus), which rendered photon radiotherapy unable to meet the required dose constraints, proton therapy was employed with the following dose prescriptions: for pulmonary metastases: CTV 50 Gy(RBE) in 15 fractions, GTV 60 Gy(RBE) in 15 fractions; for the cervical lesion: GTVnd 70 Gy(RBE) in 28 fractions, CTVnd 66 Gy(RBE) in 28 fractions, CTV 50.4 Gy(RBE) in 28 fractions. Follow-up PET/CT post-treatment demonstrated complete resolution of some bilateral pulmonary metastases, with marked reduction in size and decreased metabolism in the remaining nodules. The metastatic cervical lymph nodes also showed reduced volume and metabolic activity. No adverse events exceeding Grade 2 occurred during the treatment course. This case demonstrates that proton therapy is highly suitable for multifocal ACC metastases, especially multiple small pulmonary nodules. Through its precise dose delivery, it enables high-dose irradiation (GTV 60-70 Gy(RBE)) to targets while significantly sparing normal organs. This approach represents a viable strategy for complex cases where conventional radiotherapy is contraindicated. It aims to delay disease progression and achieve organ preservation in refractory ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.